TCRX Q2 2022 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+42.4% YoY

Gross Profit

-$10M-257.3% margin

Operating Income

-$15M-375.9% margin

Net Income

-$15M-372.2% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

+34.3%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$15M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$152M

Total Liabilities

$21M

Stockholders' Equity

$132M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+42.4%
Gross Profit	-$10M	-$8M	-31.2%
Operating Income	-$15M	-$11M	-42.8%
Net Income	-$15M	-$11M	-41.4%